[1]BioorganicandMedicinalChemistry,2013,vol.21,p.5955-5962
[2]JournalofMedicinalChemistry,2009,vol.52,p.4115-4118
[3]BioorganicandMedicinalChemistryLetters,2015,vol.25,p.3956-3960
[1]Cheung,ChiWai;LeendertPloeger,Marten;Hu,Xile[ChemicalScience,2018,vol.9,#3,p.655-659]
Title: Functional and pharmacological characteristics of metabotropic glutamate receptors 2/4 heterodimers.
Journal: Molecular pharmacology 20120901
Title: Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.
Journal: Journal of medicinal chemistry 20111110
Title: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators.
Journal: Journal of medicinal chemistry 20110728
Title: Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats.
Journal: Journal of medicinal chemistry 20110224
Title: Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs).
Journal: Journal of medicinal chemistry 20090723
Title: Engers DW, et al. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem. 2009 Jul 23;52(14):4115-8.
Title: Engers DW, et al. Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. J Med Chem. 2011 Feb 24;54(4):1106-10.
Title: Jantas D, et al. Neuroprotective effects of mGluR II and III activators against staurosporine- and doxorubicin-induced cellular injury in SH-SY5Y cells: New evidence for a mechanism involving inhibition of AIF translocation. Neurochem Int. 2015 Sep;88:124-37.
